Hsbc Holdings PLC Purchases 222,327 Shares of Encompass Health Corporation $EHC

Hsbc Holdings PLC increased its position in Encompass Health Corporation (NYSE:EHC) by 412.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 276,194 shares of the company’s stock after acquiring an additional 222,327 shares during the period. Hsbc Holdings PLC’s holdings in Encompass Health were worth $29,606,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EHC. Rockefeller Capital Management L.P. raised its stake in shares of Encompass Health by 81.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,568 shares of the company’s stock worth $379,000 after purchasing an additional 1,606 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Encompass Health by 109.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 761 shares of the company’s stock worth $81,000 after buying an additional 398 shares in the last quarter. MidFirst Bank purchased a new position in Encompass Health in the 4th quarter worth about $202,000. Virtu Financial LLC bought a new position in Encompass Health during the 4th quarter valued at about $371,000. Finally, Dean Capital Management lifted its stake in Encompass Health by 3.2% during the 4th quarter. Dean Capital Management now owns 19,763 shares of the company’s stock valued at $2,098,000 after acquiring an additional 611 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Patrick William Tuer sold 682 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the sale, the executive vice president owned 24,755 shares in the company, valued at approximately $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Encompass Health Trading Up 0.5%

Shares of EHC stock opened at $106.98 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $10.61 billion, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The stock’s 50-day moving average price is $103.20 and its 200-day moving average price is $103.39.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the business posted $1.37 EPS. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts predict that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be issued a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is 12.69%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Barclays reduced their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. TD Cowen began coverage on shares of Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 price objective on the stock. Weiss Ratings downgraded shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, June 26th. Leerink Partners set a $152.00 target price on shares of Encompass Health in a research note on Friday, May 22nd. Finally, Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Encompass Health presently has an average rating of “Moderate Buy” and a consensus target price of $143.86.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.